Experts say risks of long-term use still outweigh possible benefits
SUNDAY, Aug. 9 (HealthDay News) -- Hormone replacement therapy once seemed like a wonderful means to help women age gracefully. By dosing menopausal women with estrogen and progesterone as their bodies began to produce decreased amounts of those hormones, doctors believed they could help fend off heart disease, osteoporosis and cancer.
But those beliefs collapsed in 2002, when researchers pulled the plug three years early on the Women's Health Initiative, a large-scale, federally funded study of hormone replacement therapy (HRT). They had found that the therapy produced an increased risk of breast cancer, heart attack, stroke and blood clots. HRT has been pretty much taboo ever since.
Or has it?
Several studies released in the past year have revealed ways in which HRT might still be beneficial. Under certain conditions and with the right timing, they found, some women could be helped by the therapy.
Despite these findings, experts with the American Cancer Society and the American Heart Association say there's scant chance there will be any revision on the position on HRT in the United States anytime in the near future.
"In an effort to decrease hot flashes, it's hard to tell someone to take the breast cancer risk and the heart and stroke risk shown in other studies," said Dr. Vincent Bufalino, a spokesman for the American Heart Association and president and chief executive of Midwest Heart Specialists, in Naperville, Ill. "If you can put up with the menopausal symptoms, you're better off doing that than taking the risks related to hormone replacement therapy."
Research that has shown the more positive side of HRT has included:
The American and Danish studies also found that HRT involving just estrogen was far safer than HRT that included a combination of estrogen and progesterone.
Based on research like this, Canadian doctors are revising their guidelines on hormone replacement therapy.
But Bufalino and Susan M. Gapstur, vice president of epidemiology for the American Cancer Society, said that the studies do not provide enough evidence to sway current medical thinking in the United States.
"I would not say the philosophy is changing," Gapstur said. "The critical question becomes, there's this balance between the long-term risk of chronic diseases versus immediate concerns of hot flashes and quality of life around the postmenopausal period."
Short-term use of hormone replacement therapy might be helpful in alleviating menopause symptoms, she said, but more study is needed to fully assess the impact of that therapy -- particularly because the younger women who might benefit most from such therapy appear to be most at risk.
"What we thought we knew about hormone replacement therapy and cardiovascular disease might not be true for older women, but I think there are still a lot of questions about the risks and benefits of hormone replacement therapy for younger women," Gapstur said. "That's where we need to focus our attention."
Bufalino agrees, arguing there's little point in pushing such therapy when there's so much downside and so little benefit.
"There are some small subgroups inside the groups that show some statistical benefit, but I think we would all be cautious at this time based on this report," Bufalino said of the American Cancer Society research. "If you just look at it on the surface, it's not clearly definitive."
And perhaps adding fuel to the fire of doubts, reports emerged Aug. 5 that a pharmaceutical company that makes HRT had paid a medical communications firm to help produce 26 studies supporting its use. Those studies were published in 18 medical journals between 1998 and 2005, according to a report first published by the New York Times.
The drug maker, Wyeth, contends that the studies were scientifically accurate. None of the papers disclosed Wyeth's role in initiating and funding the work.
The U.S. National Institutes of Health has more on hormone therapy.
SOURCES: Vincent Bufalino, M.D., president and CEO, Midwest Heart Specialists, chairman, Midwest Heart Foundation, and medical director, Edward Heart Hospital, Naperville, Ill.; Susan M. Gapstur, Ph.D., M.P.H., vice president, epidemiology, American Cancer Society; April 22, 2009, presentation, American Association for Cancer Research annual meeting, Denver; American Cancer Society, news release, Feb. 2, 2009; Oct. 1, 2008, European Heart Journal, online; Sept. 23, 2008, Journal of the National Cancer Institute
All rights reserved